Perrigo Company (NYSE:PRGO) EVP John Wesolowski acquired 700 shares of the firm’s stock in a transaction dated Thursday, December 14th. The stock was bought at an average cost of $85.80 per share, for a total transaction of $60,060.00. The purchase was disclosed in a document filed with the SEC, which is available through this link.
John Wesolowski also recently made the following trade(s):
- On Thursday, December 7th, John Wesolowski sold 450 shares of Perrigo stock. The stock was sold at an average price of $83.09, for a total value of $37,390.50.
- On Wednesday, November 29th, John Wesolowski sold 388 shares of Perrigo stock. The stock was sold at an average price of $87.20, for a total value of $33,833.60.
Perrigo Company (NYSE:PRGO) opened at $91.99 on Friday. The company has a market capitalization of $12,690.00, a price-to-earnings ratio of -10.04, a PEG ratio of 1.92 and a beta of 0.64. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.72 and a quick ratio of 1.24. Perrigo Company has a 1 year low of $63.68 and a 1 year high of $92.16.
The business also recently declared a quarterly dividend, which was paid on Tuesday, December 19th. Stockholders of record on Friday, December 1st were given a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.70%. The ex-dividend date was Thursday, November 30th. Perrigo’s payout ratio is -6.99%.
Several research analysts have recently commented on the company. Cantor Fitzgerald set a $107.00 price objective on Perrigo and gave the stock a “buy” rating in a research note on Thursday, December 28th. Leerink Swann initiated coverage on Perrigo in a research report on Tuesday, January 2nd. They set a “market perform” rating and a $90.00 target price for the company. Canaccord Genuity set a $100.00 target price on Perrigo and gave the stock a “buy” rating in a research report on Monday, January 1st. Jefferies Group reiterated a “hold” rating and set a $81.00 target price on shares of Perrigo in a research report on Friday, November 10th. Finally, Oppenheimer initiated coverage on Perrigo in a research report on Monday, October 2nd. They set a “buy” rating and a $88.00 target price for the company. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the stock. Perrigo currently has an average rating of “Hold” and a consensus target price of $92.00.
Several institutional investors and hedge funds have recently added to or reduced their stakes in PRGO. Commonwealth Bank of Australia raised its position in shares of Perrigo by 13.8% in the 2nd quarter. Commonwealth Bank of Australia now owns 1,455 shares of the company’s stock worth $108,000 after acquiring an additional 176 shares in the last quarter. Bessemer Group Inc. raised its position in shares of Perrigo by 1,046.2% in the 2nd quarter. Bessemer Group Inc. now owns 2,235 shares of the company’s stock worth $169,000 after acquiring an additional 2,040 shares in the last quarter. Allianz Asset Management GmbH bought a new position in shares of Perrigo in the 3rd quarter worth $217,000. Conning Inc. bought a new position in shares of Perrigo in the 3rd quarter worth $219,000. Finally, BlueCrest Capital Management Ltd bought a new position in shares of Perrigo in the 2nd quarter worth $221,000. 83.29% of the stock is owned by hedge funds and other institutional investors.
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.